Prediction of resistance to chemotherapy in ovarian cancer: A systematic review

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Lloyd, Katherine L ^a   Cree, Ian A ^b   Savage, Richard S ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Chemoresistance; Ovarian cancer; Predictive model; Statistical modelling

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CHEMOSENSITIVITY; DISEASE FREE SURVIVAL; DRUG RESPONSE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOLOGY; HUMAN; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; OVARIAN NEOPLASMS; PREDICTIVE VALUE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS;

EID: 84925300699     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1101-8     Document Type: Article

References (89)

1. Office for National Statistics: Cancer Incidence and Mortality in the United Kingdom. 2008-2010. http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2008-2010/rft-cancer-incidence-and-mortality-in-the-uk--2008-2010.xls.
2. Office for National Statistics: Cancer Survival Rates, Cancer Survival in England, Patients Diagnosed 2005-2009 and Followed up to 2010. http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-survival-rates/2005-2009--followed-up-to-2010/tbl-cancer-survival.xls.
3. Li M, Yin J, Mao N, Pan L. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. Oncology Rep. 2013; 29(1):58-66.
4. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999; 93(1):21-4.
5. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The Oncologist. 2002; 7(Supplement 5):20-8.
6. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al.Cancer cell adaptation to chemotherapy. BMC Cancer. 2005; 5(1):78.
7. National Institute for Health and Care Excellence: Guidance on the use of paclitaxel in the treatment of ovarian cancer. http://www.nice.org.uk/guidance/ta55.
8. Goff BA. Advanced ovarian cancer: what should be the standard of care?J Gynecol Oncol. 2013; 24(1):83-91.
9. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al.Prognostic factors for stage iii epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2007; 25(24):3621-7.
10. Cancer Research UK: Ten-year survival over time. http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/generalcontent/surv_10yrtrends_selcancers_xls.xls.
11. ™ 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009; 9(5):417-22.
12. ®: Underlying Technology. http://breast-cancer.oncotypedx.com/en-US/Professional-Invasive/WhatIsTheOncotypeDXBreastCancerTest/UnderlyingTechnology.aspx.
13. ®: What Is the Colon cancer test? http://colon-cancer.oncotypedx.com/en-US/Professional/WhatIsTheColonCancerTest.aspx.
14. ®: Development. http://prostate-cancer.oncotypedx.com/en-US/Professional/IntroducingGPS/Development.aspx.
15. Efron B. The efficiency of cox's likelihood function for censored data. J Am Stat Assoc. 1977; 72(359):557-65.
16. Gillet J-P, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al.Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Nat Acad Sci. 2011; 108(46):18708-13.
17. Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010; 10(4):375-9.
18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36.
19. The Oxford 2011 Levels of Evidence (OCEBM Levels of Evidence Working Group). http://www.cebm.net/index.aspx?o=5653.
20. Wang X, Terfve C, Rose JC, Markowetz F. Htsanalyzer: an r/bioconductor package for integrated network analysis of high-throughput screens. Bioinformatics. 2011; 27(6):879.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995; 57(1):289-300.
22. Jeong W, Kim S-B, Sohn BH, Park Y-Y, PARK ES, Kim SC, et al.Activation of yap1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014; 34(2):811-7.
23. Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Kujawa K, Grzybowska E, et al.Gene expression analysis in ovarian cancer - faults and hints from dna microarray study. Front Oncol. 2014; 4:6.
24. Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, et al.Class iii beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis. 2014; 31(1):101-10.
25. Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, et al.Stem cell-like gene expression in ovarian cancer predicts type ii subtype and prognosis. PLoS One. 2013; 8:57799.
26. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al.Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013; 123(1):517-25.
27. Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, et al.Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the ovcad consortium. Gynecol Oncol. 2013; 128(1):15-21.
28. Han Y, Huang H, Xiao Z, Zhang W, Cao Y, Qu L, et al.Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One. 2012; 7:52745.
29. Hsu FH, Serpedin E, Hsiao TH, Bishop AJ, Dougherty ER, Chen Y. Reducing confounding and suppression effects in tcga data: an integrated analysis of chemotherapy response in ovarian cancer. BMC Genomics. 2012; 13 Suppl 6:13.
30. Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, et al.Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7:36383.
31. Kang J, D'Andrea AD, Kozono D. A dna repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012; 104:670-81.
32. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, et al.Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res. 2012; 18:3197-206.
33. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, et al.Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012; 7:30550.
34. Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Darai E. Expression of mmp-2, -7, -9, mt1-mmp and timp-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep. 2012; 27(4):1049-57.
35. Skirnisdottir I, Seidal T. The apoptosis regulators p53, bax and puma: Relationship and impact on outcome in early stage (figo i-ii) ovarian carcinoma after post-surgical taxane-based treatment. Oncol Rep. 2012; 27(3):741-7.
36. Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B. Expression of the ets transcription factor ehf in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol. 2012; 43(4):496-505.
37. Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E, et al.A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer. 2011; 105:304-11.
38. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, et al.Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011; 8(6):2080-8.
39. Chao SY, Chiang JH, Huang AM, Chang WS. An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Med Genomics. 2011; 4:23.
40. Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR. Molecular clustering based on eralpha and eig121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011; 24:453-62.
41. Glaysher S, Gabriel FG, Johnson P, Polak M, Knight LA, Parker K, et al.Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer. 2010; 103:656-62.
42. Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin a3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010; 70:1616-24.
43. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, et al.Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 2010; 5(3):9615.
44. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, et al.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 2009; 69:8302-9.
45. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D, et al.A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol. 2009; 218(2):273-80.
46. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al.Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009; 7:210-20.
47. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, et al.Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009; 6:24.
48. Mendiola M, Barriuso J, Redondo A, Marino-Enriquez A, Madero R, Espinosa E, et al.Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS One. 2008; 3(12):4051.
49. Gevaert O, De Smet F, Van Gorp T, Pochet N, Engelen K, Amant F, et al.Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer. 2008; 8:18.
50. Bachvarov D, L'Esperance S, Popa I, Bachvarova M, Plante M, Tetu B. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol. 2006; 29(4):919-33.
51. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A. Wt1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer. 2006; 6:90.
52. De Smet F, Pochet NL, Engelen K, Van Gorp T, Van Hummelen P, Marchal K, et al.Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer. 2006; 16 Suppl 1:147-51.
53. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, et al.Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006; 118(8):1963-71.
54. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, et al.Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005; 23:7911-8.
55. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, et al.Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005; 11:6300-10.
56. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL. Increased cyclooxygenase-2 (cox-2) and p-glycoprotein-170 (mdr1) expression is associated with chemotherapy resistance and poor prognosis. analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer. 2005; 15:255-60.
57. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, et al.Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005; 11:2149-55.
58. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al.Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004; 22:4700-10.
59. Selvanayagam ZE, Cheung TH, Wei N, Vittal R, Lo KW, Yeo W, et al.Prediction of chemotherapeutic response in ovarian cancer with dna microarray expression profiling. Cancer Genet Cytogenet. 2004; 154:63-6.
60. Iba T, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Simada M, et al.Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci. 2004; 95(5):418-23.
61. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, et al.Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002; 86:171-6.
62. Vogt U, Falkiewicz B, Bielawski K, Bosse U, Schlotter CM. Relationship of c-myc and erbb oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified atp-chemosensitivity assay. Acta Biochim Pol. 2000; 47(1):157-64.
63. Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC. Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med. 2007; 131(12):1805-16.
64. Rentoft M, Coates PJ, Laurell G, Nylander K. Transcriptional profiling of formalin fixed paraffin embedded tissue: pitfalls and recommendations for identifying biologically relevant changes. PloS One. 2012; 7(4):35276.
65. Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment. J Exp Clin Cancer Res. 2012; 31(53):35.
66. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al.Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004; 22(6):1040-4.
67. Oldenhuis C, Oosting S, Gietema J, De Vries E. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008; 44(7):946-53.
68. Tezak Z, Kondratovich MV, Mansfield E. Us fda and personalized medicine: in vitro diagnostic regulatory perspective. Personalized Med. 2010; 7(5):517-30.
69. Tapia G, Diaz-Padilla I. Molecular mechanisms of platinum resistance in ovarian cancer In: Diaz-Padilla I, editor. Ovarian Cancer - A Clinical and Translational Update. InTech: 2013.
70. Citri A, Yarden Y. Egf-erbb signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16.
71. Tan F, Thiele CJ, Zhijie L. Neurotrophin signaling in cancer In: Kostrzewa RM, editor. Handbook of Neurotoxicity. New York: Springer: 2014.
72. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer. 2005; 5(7):505-15.
73. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005; 23(9):2078-93.
74. Levine AJ, Bargonetti J, Bond GL, Hoh J, Onel K, Overholtzer M, et al.The p53 network In: Zambetti GP, editor. The P53 Tumor Suppressor Pathway and Cancer. US: Springer: 2005.
75. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: A review of molecular epidemiological studies. Mol Carcinog. 2005; 42(2):65-92.
76. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of dna repair pathways. Clin Cancer Res. 2008; 14(5):1291-5.
77. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007; 2(7):920-42.
78. Jekunen A, Christen R, Shalinsky D, Howell S. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. British J Cancer. 1994; 69(2):299.
79. Hall A, Tilby M. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992; 6(3):163-73.
80. Pópulo H, Lopes JM, Soares P. The mtor signalling pathway in human cancer. Int J Mol Sci. 2012; 13(2):1886-918.
81. Dhillon A, Hagan S, Rath O, Kolch W. Map kinase signalling pathways in cancer. Oncogene. 2007; 26(22):3279-90.
82. Hembruff SL, Cheng N. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther. 2009; 7(A):254.
83. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clinical Cancer Res. 2006; 12(17):5018-22.
84. Cree IA. Designing personalised cancer treatments. J Control Release. 2013; 172(2):405-9.
85. Bernstein C, Prasad AR, Nfonsam V, Bernstein H. Dna damage, dna repair and cancer In: Chen C, editor. New Research Directions in DNA Repair. InTech: 2013.
86. Royston P, Altman DG. External validation of a cox prognostic model: principles and methods. BMC Med Res Methodol. 2013; 13(1):33.
87. Heagerty PJ, Lumley T, Pepe MS. Time-dependent roc curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44.
88. Altman DG, Royston P. Statistics notes: the cost of dichotomising continuous variables. BMJ: British Med J. 2006; 332(7549):1080.
89. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.